Technical Analysis for BCTX - BriaCell Therapeutics Corp.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 2.90 | -1.69% | -0.05 |
BCTX closed down 1.69 percent on Monday, March 18, 2024, on approximately normal volume. The bears made the stock sink to a new 52-week low. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Hammer Candlestick | Bullish | 0.00% | |
Lizard Bullish | Bullish Day Trade Setup | 0.00% | |
New 52 Week Low | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Narrow Range Bar | Range Contraction | -1.69% | |
Inside Day | Range Contraction | -1.69% | |
Oversold Stochastic | Weakness | -1.69% | |
New Downtrend | Bearish | -2.68% | |
Lizard Bullish | Bullish Day Trade Setup | -2.68% |
Alert | Time |
---|---|
Lower Bollinger Band Support | about 11 hours ago |
2x Volume Pace | about 12 hours ago |
3x Volume Pace | about 12 hours ago |
Down 10% | about 12 hours ago |
1.5x Volume Pace | about 12 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/11/2024
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immune System Immunotherapy Oncology Breast Cancer Treatment Of Breast Cancer Immune Checkpoint National Cancer Institute Advanced Breast Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immune System Immunotherapy Oncology Breast Cancer Treatment Of Breast Cancer Immune Checkpoint National Cancer Institute Advanced Breast Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 7.75 |
52 Week Low | 2.6206 |
Average Volume | 90,055 |
200-Day Moving Average | 5.22 |
50-Day Moving Average | 3.76 |
20-Day Moving Average | 3.23 |
10-Day Moving Average | 3.01 |
Average True Range | 0.26 |
RSI (14) | 31.97 |
ADX | 28.46 |
+DI | 9.63 |
-DI | 31.96 |
Chandelier Exit (Long, 3 ATRs) | 2.96 |
Chandelier Exit (Short, 3 ATRs) | 3.39 |
Upper Bollinger Bands | 3.72 |
Lower Bollinger Band | 2.74 |
Percent B (%b) | 0.17 |
BandWidth | 30.49 |
MACD Line | -0.24 |
MACD Signal Line | -0.24 |
MACD Histogram | -0.0003 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.44 | ||||
Resistance 3 (R3) | 3.41 | 3.19 | 3.35 | ||
Resistance 2 (R2) | 3.19 | 3.06 | 3.21 | 3.32 | |
Resistance 1 (R1) | 3.05 | 2.97 | 2.94 | 3.08 | 3.29 |
Pivot Point | 2.83 | 2.83 | 2.78 | 2.85 | 2.83 |
Support 1 (S1) | 2.69 | 2.70 | 2.58 | 2.72 | 2.51 |
Support 2 (S2) | 2.47 | 2.61 | 2.49 | 2.48 | |
Support 3 (S3) | 2.33 | 2.47 | 2.45 | ||
Support 4 (S4) | 2.36 |